Testing empasiprubart for generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tested positive for a specific antibody (AChR-Ab) linked to myasthenia gravis.
- Your MGFA class is II, III, IVa, or IVb (mild to severe symptoms—but not needing a breathing tube).
- You are up to date on vaccines for bacterial meningitis and pneumonia, or can get them before the trial starts.
- You are not currently taking a complement inhibitor (like eculizumab) or efgartigimod within the last 4 weeks.
- You have never taken empasiprubart before.
- You do not have lupus (SLE).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study tests a new medicine called ripertamab for people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The medicine aims to reduce the immune system's attack on muscles, which may help improve daily activities and quality of life.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
Hear when a new AChR-Ab Seropositive Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.